|
|
|
|
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
Autosomal Dominant Hypocalcemia Types 1 and 2 (ADH1/2) Disease Monitoring Study (DMS) - ADH1DMP
An open label, single-dose, single-period study designed to assess the mass balance recovery, metabolite profile and metabolite identification of [14C]encaleret in healthy male subjects
CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
100 项与 Calcilytix Therapeutics, Inc. 相关的临床结果
0 项与 Calcilytix Therapeutics, Inc. 相关的专利(医药)
100 项与 Calcilytix Therapeutics, Inc. 相关的药物交易
100 项与 Calcilytix Therapeutics, Inc. 相关的转化医学